Salvage Therapies After Anti-BCMA CAR-T Failure in Patients With Multiple Myeloma: A Meta-Analysis of Response Rates
HematologiaSobre o estudo
- Desenho
- Metanálise
- Nível de evidência
- 1 · Evidência consolidada
- Revista
- European journal of haematology
- Publicado em
- 27 jan 2026
- Citações
- 0
O resumo deste estudo é do publisher e não tem licença aberta: por isso mostramos aqui só os dados do estudo, e o texto fica na fonte original, nos links abaixo.
O estudo original
Salvage Therapies After Anti-BCMA CAR-T Failure in Patients With Multiple Myeloma: A Meta-Analysis of Response Rates
Jaromir Tomasik, Roni Shouval, Anat Gafter-Gvili, Julia Topiłko, Dominik Bilicki, Grzegorz W Basak
Descritores MeSH
- B-Cell Maturation Antigen
- Multiple Myeloma
- Immunotherapy, Adoptive
- Salvage Therapy
- Receptors, Chimeric Antigen
- Humans
- Treatment Outcome
- Treatment Failure
- Antibodies, Bispecific
Veja também
Estudos relacionados
- A systematic review of indirect treatment comparisons among recently approved chimeric antigen receptor T-cell and bispecific antibody therapies for triple-class exposed relapsed/refractory multiple myeloma
- Efficacy of bispecific T-cell engagers after CAR T-cell therapy failure in aggressive large B-cell lymphoma
- Allogeneic hematopoietic stem cell transplantation following T-cell-directed immunotherapy failure in B-cell lymphoma: a real-world case series and systematic literature review
- Comparative efficacy and safety of BCMA-targeted CAR T cells and BiTEs in relapsed/refractory multiple myeloma: a meta-analysis of interventional and real-world studies